Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew T Nishimoto

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
The Journal of Antimicrobial Chemotherapy|October 12, 2019
Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicansAndrew T Nishimoto, Cheshta Sharma, P David Rogers
Frontiers in Microbiology|July 28, 2020
Pneumolysin: Pathogenesis and Therapeutic TargetAndrew T Nishimoto, Jason W Rosch, Elaine I Tuomanen
Pharmacotherapy|November 25, 2015
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal AgentJeffrey M Rybak, Kayleigh R Marx, Andrew T Nishimoto, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2019
Contribution of Clinically Derived Mutations in the Gene Encoding the Zinc Cluster Transcription Factor Mrr2 to Fluconazole Antifungal Resistance and <i>CDR1</i> Expression in <i>Candida albicans</i>Andrew T Nishimoto, Qing Zhang, Brandon Hazlett, et al.
Antimicrobial Agents and Chemotherapy|February 6, 2019
Abrogation of Triazole Resistance upon Deletion of <i>CDR1</i> in a Clinical Isolate of <i>Candida auris</i>Jeffrey M Rybak, Laura A Doorley, Andrew T Nishimoto, et al.
Frontiers in Microbiology|January 28, 2017
Azole Antifungal Resistance in <i>Candida albicans</i> and Emerging Non-<i>albicans Candida</i> SpeciesSarah G Whaley, Elizabeth L Berkow, Jeffrey M Rybak, et al.
Cell Reports|December 14, 2022
Interspecies recombination, not de novo mutation, maintains virulence after β-lactam resistance acquisition in Streptococcus pneumoniaeAndrew T Nishimoto, Tina H Dao, Qidong Jia, et al.
Antimicrobial Agents and Chemotherapy|March 13, 2019
A Systematic Screen Reveals a Diverse Collection of Medications That Induce Antifungal Resistance in <i>Candida</i> SpeciesArielle Butts, Parker Reitler, Andrew T Nishimoto, et al.
Antimicrobial Agents and Chemotherapy|February 21, 2019
The Evolution of Azole Resistance in <i>Candida albicans</i> Sterol 14α-Demethylase (CYP51) through Incremental Amino Acid SubstitutionsAndrew G Warrilow, Andrew T Nishimoto, Josie E Parker, et al.
Antimicrobial Agents and Chemotherapy|August 7, 2019
Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161Andrew T Nishimoto, Sarah G Whaley, Nathan P Wiederhold, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
The Journal of Antimicrobial Chemotherapy|October 12, 2019
Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicansAndrew T Nishimoto, Cheshta Sharma, P David Rogers
Frontiers in Microbiology|July 28, 2020
Pneumolysin: Pathogenesis and Therapeutic TargetAndrew T Nishimoto, Jason W Rosch, Elaine I Tuomanen
Pharmacotherapy|November 25, 2015
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal AgentJeffrey M Rybak, Kayleigh R Marx, Andrew T Nishimoto, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2019
Contribution of Clinically Derived Mutations in the Gene Encoding the Zinc Cluster Transcription Factor Mrr2 to Fluconazole Antifungal Resistance and <i>CDR1</i> Expression in <i>Candida albicans</i>Andrew T Nishimoto, Qing Zhang, Brandon Hazlett, et al.
Antimicrobial Agents and Chemotherapy|February 6, 2019
Abrogation of Triazole Resistance upon Deletion of <i>CDR1</i> in a Clinical Isolate of <i>Candida auris</i>Jeffrey M Rybak, Laura A Doorley, Andrew T Nishimoto, et al.
Frontiers in Microbiology|January 28, 2017
Azole Antifungal Resistance in <i>Candida albicans</i> and Emerging Non-<i>albicans Candida</i> SpeciesSarah G Whaley, Elizabeth L Berkow, Jeffrey M Rybak, et al.
Cell Reports|December 14, 2022
Interspecies recombination, not de novo mutation, maintains virulence after β-lactam resistance acquisition in Streptococcus pneumoniaeAndrew T Nishimoto, Tina H Dao, Qidong Jia, et al.
Antimicrobial Agents and Chemotherapy|March 13, 2019
A Systematic Screen Reveals a Diverse Collection of Medications That Induce Antifungal Resistance in <i>Candida</i> SpeciesArielle Butts, Parker Reitler, Andrew T Nishimoto, et al.
Antimicrobial Agents and Chemotherapy|February 21, 2019
The Evolution of Azole Resistance in <i>Candida albicans</i> Sterol 14α-Demethylase (CYP51) through Incremental Amino Acid SubstitutionsAndrew G Warrilow, Andrew T Nishimoto, Josie E Parker, et al.
Antimicrobial Agents and Chemotherapy|August 7, 2019
Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161Andrew T Nishimoto, Sarah G Whaley, Nathan P Wiederhold, et al.
Pageof 2